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A novel poly-ε-lysine based implant, Proliferate®,
for promotion of CNS repair following spinal cord
injury†
Sara Hosseinzadeh,a Susan L. Lindsay, a Andrew G. Gallagher, b
Donald A. Wellings,b Mathis O. Riehle, c John S. Riddelld and Susan C. Barnett *a
The limited regenerative capacity of the CNS poses formidable challenges to the repair of spinal cord
injury (SCI). Two key barriers to repair are (i) the physical gap left by the injury, and (ii) the inhibitory milieu
surrounding the injury, the glial scar. Biomaterial implantation into the injury site can fill the cavity, provide
a substrate for cell migration, and potentially attenuate the glial scar. We investigated the biological viabi-
lity of a biocompatible and biodegradable poly-ε-lysine based biomaterial, Proliferate®, in low and high
cross-linked forms and when coated with IKVAV peptide, for SCI implantation. We demonstrate altered
astrocyte morphology and nestin expression on Proliferate® compared to conventional glass cell cover-
slips suggesting a less reactive phenotype. Moreover Proliferate® supported myelination in vitro, with
myelination observed sooner on IKVAV-coated constructs compared with uncoated Proliferate®, and
delayed overall compared with maintenance on glass coverslips. For in vivo implantation, parallel-aligned
channels were fabricated into Proliferate® to provide cell guidance cues. Extensive vascularisation and
cellular infiltration were observed in constructs implanted in vivo, along with an astrocyte border and
microglial response. Axonal ingrowth was observed at the construct border and inside implants in intact
channels. We conclude that Proliferate® is a promising biomaterial for implantation following SCI.
1. Introduction
Mechanical damage to the spinal cord in traumatic spinal
cord injury (SCI) typically induces haemorrhage, blood-spinal
cord barrier (BSCB) breakdown, oedema, axonal disruption
and demyelination at the injury site.1 Over time, the injury pro-
gresses to secondary and chronic phases commonly compris-
ing cystic cavitation, axonal dieback, demyelination and the
formation of a perilesional glial scar.1,2 Several strategies have
been proposed as promising treatments for SCI ranging from
cell transplantation to biomaterial implantation.2 Peripheral
nerve grafts implanted into the injured spinal cord have long
been known to promote central nervous system (CNS) regener-
ation by providing a supportive substratum for guided axonal
growth.3–8 However, allogenic peripheral nerve transplantation
necessitates long term immunosuppression and autologous
transplantation requires further, often non-recoverable,
surgery at a secondary site, thereby compounding the existing
risk of surgical complications.9 Biocompatible materials can
circumvent this unnecessary harm, providing a substrate for
regeneration, a delivery vessel for cell and pharmaceutical
therapies,10–13 and a bridge across cystic cavities formed in
intermediate stages of SCI.14–16
There is evidence for progressive neurodegeneration and
spinal cord atrophy years after SCI,17 with cavity expansion
and continuing die-back of axonal tracts. In pre-clinical
studies, cell transplantation reduces injury area as SCI pro-
gresses to chronic stages, a finding primarily limited to acute
and subacute injury phase transplantations.18,19 This demon-
strates the neuroprotective potential of cell transplantation
and consequent physical reconstruction of the injury site.
However, cell transplantation in human SCI poses a number of
challenges, including generation of cells at numbers high
enough to fill large injury cavities and long-term localisation
of transplanted cells to the lesion site. By incorporating cells
with biomaterials prior to transplantation, cells can be more
accurately localised to the lesion site than by injection alone
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and can be transplanted at lower densities, with the material
acting as a substitute ECM to fill the cavity.10 Several materials,
both natural and synthetic, have thus far been investigated for
this purpose. The mammalian extracellular matrix (ECM) is an
obvious source of natural biomaterials for regeneration, due to
its existing cell-supportive role. Indeed, several ECM com-
ponents have been investigated for SCI implantation, includ-
ing collagen, fibrin, hyaluronic acid and laminin.10,12,20–24
Synthetic polymers, however, are often favoured over natural
materials for mass reproducibility.10,12 These polymers can be
enriched by incorporation of functional ECM peptides. The
most extensively investigated examples of these in CNS repair
are Arg-Gly-Asp (RGD), the cell adhesive region of ECM pro-
teins such as laminin and fibronectin,20–24 and Ile-Lys-Val-Ala-
Val [IKVAV], a functional peptide of laminin.23–27 In particular,
IKVAV has been shown to promote neuronal plasticity and
improved functional outcomes following rodent SCI.28,29
Proliferate®, a polymer based on cross-linked poly-ε-lysine
[pεK], is a macroporous, biocompatible and biodegradable
material with tuneable porosity. It is composed of two natu-
rally occurring components, pεK and a di-carboxylic acid (e.g.
decanedioic acid, tridecanedioic acid), breaks down upon
decomposition into natural, non-toxic components, and is
reproducible on a mass scale. It is a soft, flexible material
interspersed with macropores that allow for waste and nutrient
exchange, and can bind other bioactive compounds at carboxyl
and amine moieties. These included amphotericin B and peni-
cillin G to provide a drug eluting capacity to advanced corneal
bandage lenses and addition of the cell binding peptide H-Gly-
Gly-Arg-Gly-Asp-Gly-Gly-OH (RGD) as well as fragments of
larger proteins such as collagen and fibronectin to promote
binding and expansion of corneal endothelial cells
in vitro.30–32
Here we report that Proliferate®, both in original form and
when modified by coating in IKVAV, is also a promising candi-
date for SCI implantation, meeting several criteria for bioma-
terials in this field including support of CNS cells, integration




Reagents and scaffolds were provided by SpheriTech Ltd
(Runcorn, Cheshire, UK). Proliferate® was synthesised from
pεK (Zhengzhou Bainafo Bioengineering Co. Ltd, Zhengzhou,
China) and cross-linked to 95% (excess amine functional
groups) or 105% (excess carboxyl functional groups) with a
mix of decanedioic (Sigma Aldrich, Dorset, UK) and tridecane-
dioic acids (Shanghai Worldyang Chemical Co. Ltd, Shanghai,
China) and a polymer density of 0.055 g ml−1 using
N-hydroxysuccinimide (NHS, CarboSynth Ltd, Berkshire, UK)
and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDCI,
CarboSynth Ltd, Berkshire, UK).
A pεK (40.9 g, 0.238 mol free amine) monomer stock solu-
tion was first prepared in dH2O (200 ml) and adjusted to pH
7.1. A separate bis-carboxylic acid cross-linker stock solution
was also made, composed of tridecanedioic acid (BA; 24.4 g,
0.2 mol of carboxylic acid function), decanedioic acid (SA;
2.24 g, 0.2 mol of carboxylic acid function) and
N-methylmorpholine (NMM; 25.6 ml, 0.233 mol) in dH2O
(200 ml). A separate stock solution of 5% (w/v) tween 80 (VWR
International Ltd, Lutterworth, UK) was also prepared. All
stock solutions were filtered separately to 0.45 µm with a
nylon + GMF syringe filter (Crawford Scientific Ltd, Strathaven,
Scotland).
To make carboxyl-functional Proliferate® (P–C, 105% cross-
linking, 50 ml), pεK monomer solution (10 ml) was combined
with bis-carboxylic acid cross-linker solution (11.3 ml) and
topped up with dH2O (25 ml). Separately, EDCI (6 g,
31.3 mmol) and NHS (0.69 g, 6 mmol) were dissolved in dH2O
(25 ml) and filter-sterilised before mixing with the pεK/bis-car-
boxylic acid solution (50 ml total volume). The solution was
mixed and immediately poured into 10 × 10 cm2 Petri dishes
(5 ml per dish). The polymer was covered and incubated over-
night at 25 °C. The sheets were then washed 1 × 10 min H2O, 3
× 30 min 0.25 M NaOH, 3 × 30 min 0.25 M HCl, and 3 ×
30 min H2O. Polymer sheets were frozen (approx. −35 °C) on
an Edwards Super Modulyo freeze dryer shelf (Edwards Ltd,
West Sussex, UK), the vacuum was then applied and they were
lyophilised overnight with the shelf reaching a final tempera-
ture of 27 °C following an incremental increase. Amine-func-
tional (P–N, 95% cross-linking, 50 ml) constructs were made
using the same protocol but with different reagent volumes
(10.5 ml pεK stock solution, 10.75 ml bis-carboxylic acid stock
solution, 0.66 g NHS, 5.72 g EDCI).
The nonapeptide H-Gly-Gly-Ile-Lys-Val-Ala-Val-Gly-Gly-OH
was prepared by solid phase synthesis and purified by reversed
phase HPLC. This peptide containing the laminin binding
sequence -Ile-Lys-Val-Ala-Val- (IKVAV) was coupled covalently to
previously prepared P–C constructs prior to freeze-drying with
0.25 M EDCI and NHS, as follows. A 1 cm length of the CNS
conduit (300 mg) with a carboxylic acid capacity of
0.035 mmol was pre-activated with 1-ethyl-3-(3-dimethyl-
aminopropyl)carbodiimide (1.91 g, 10 mmol) and N-hydroxy
succinimide (1.44 g, 12.5 mmol) in water (50 cm3) for 1 h. The
pre-activated CNS conduit was then washed with water (2 ×
50 cm3) and the nonapeptide (72 mg, 0.07 mmol) pre-dis-
solved in water (50 cm3) was added. The coupling reaction was
allowed to proceed overnight. The nonapeptide coupled
conduit was washed with water (2 × 50 cm3), sodium hydroxide
solution (0.1 mol dm−3, 50 cm3), water (2 × 50 cm3), hydro-
chloric acid solution (0.1 mol dm−3, 50 cm3) and water (2 ×
50 cm3). The water was drained off and the sample freeze
dried to yield 325 mg of nonapeptide coupled CNS conduit.
The amount of peptide coupled (25 mg) was determined
gravimetrically.
Two glycine amino acids either side of the IKVAV have been
shown to minimise aggregation (Spheritech unpublished
observations). The initial loading of IKVAV to the polymer was
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monitored via HPLC. At different time-points in the polymeris-
ation process, the supernatant was collected and run on the
HPLC to monitor the amount of peptide left in the super-
natant. The decreasing amount in the supernatant indicated
the binding of peptide to the polymer. In order to confirm the
presence of the IKVAV peptide on the carboxyl scaffold, one dry
carboxyl scaffold sample and one dry IKVAV carboxyl scaffold
sample were sent for amino acid analysis (Severn Biotech Ltd,
Kidderminster). The samples were hydrolysed and separated,
and the amino acids were detected and quantified compared
to their predicted values of 1 isoleucine, 1 lysine, 2 valine and
1 alanine. The detection of lysine was excluded because of the
large amounts of lysine found in the poly(ε-lysine) polymer.
The IKVAV carboxyl was compared to the carboxyl scaffold in
relation to their amino acid content. The coupling protocol is
well established and fully validated33 therefore the only quality
control carried out was gravimetric analysis of the construct
prior and post coupling of the peptide. IKVAV coupling to bio-
material scaffolds is a well-established procedure.34–36
To make 24-well plate construct inserts, the dry sheets were
cut to 0.64 cm2 with a size 5 borer. Blank (no membrane
attached) 24-well cell culture inserts (SABEU GmbH & Co. KG,
Northeim, Germany) were adhered to the construct using a dis-
solution/reprecipitation technique. The blank inserts were
aligned on top of the 0.64 cm2 constructs before adding
toluene dropwise (40 µl). The insert was then inverted and left
to dry for 1 h. To make tubular constructs for implantation, a
1 ml serological pipette (3 mm in diameter) was secured verti-
cally using a clamp and 300 soluble polyvinyl alcohol fibres
(100 µm diameter, soluble at 90 °C), were inserted vertically
through the pipette, and secured at each end with cable ties.
P–C was prepared as described and poured into a 1 ml syringe
upon combination with the cross-linker solution. The syringe
was inverted and attached to the serological pipette, and the
polymer solution was syringed upwards to fill the pipette. The
construct was left to set for 5 h, following which the pipette
and polymer within were cut into 40 mm segments using a
pipe cutter and scalpel respectively. The pipette sections con-
taining the construct were placed in a water bath at 100 °C for
8 h to dissolve the fibres whilst retaining morphology. The
constructs were removed from the pipette sections, washed
further with water at 100 °C (×5) and freeze-dried as described
above (see schematic in ESI Fig. 1†). The constructs were exam-
ined via SEM for wash efficiency.
Prior to cell seeding or implantation, constructs were steri-
lised in 70% ethanol for >2 h and incubated in cell culture
medium overnight. For in vivo implantation, constructs were
washed and stored in endotoxin-free PBS following sterilisa-
tion, prior to surgery.
2.2. Mechanical characterisation
Mechanical properties of Proliferate® was measured using a
Linkam TST350 tensile tester (Linkam Scientific Instruments
Ltd, Tadworth, England). Stress (σ), strain (ε) and elastic
modulus (E) were determined for each hydrated sample.
Samples were cut to a dog bone shaped piece using a bore to
provide a 15 mm test length between the clamps of the
Linkam stage. The width and thickness of each sample was
measured with an Absolute Digimatic caliper (Mitutoyo Ltd,
Andover, England) and the readings recorded. The sample was
then mounted in the Linkam tensile tester and secured in
place with the provided clamps. The software was run and
each sample was elongated until breakage point. A 20 N load
cell was used for all mechanical analysis with a strain rate of
100 μm s−1. Results were recorded and analysed using the sup-
plied Linksys32 software.
2.3. Ethical considerations
All experimental procedures were approved by the Ethical
Review Panel of the University of Glasgow and performed in
accordance with the UK Animals (Scientific Procedures) Act
1986 using ARRIVE guidelines. Animals were kept under
appropriate light and temperature conditions, with food and
water available ad libitum.
2.4. Cell culture
Primary glial and neural cells isolated from Sprague-Dawley
(SD) rats (Charles River) were maintained in a humidified incu-
bator at 37 °C with 7% atmospheric CO2. Astrocytes were cul-
tured from postnatal day 1 (P1) rat neurospheres according to
standard methods previously described.37 Briefly, neuro-
spheres were obtained from striatum dissections, cultured for
7–10 days in vitro (DIV), resuspended and cultured in astrocyte
culture media (10% foetal bovine serum (FBS) in low glucose
Dulbecco’s modified Eagle’s medium (DMEM), both
ThermoFisher). Astrocyte cultures were fed twice weekly and
reached confluency at 5–7 DIV. Myelinating cultures were gen-
erated from embryonic day 15 (E15) rats and seeded onto con-
fluent neurosphere-derived astrocyte monolayers as previously
described.37 E15 spinal cord preparations were initially cul-
tured in high glucose DMEM (ThermoFisher) containing 10 ng
ml−1 biotin (Sigma-Aldrich), 50 nM N1 medium supplement
(Sigma-Aldrich), 50 nM hydrocortisone (Sigma-Aldrich) and
0.5 mg ml−1 bovine insulin (ThermoFisher) for 12 days.
Insulin was removed from culture media for the remaining
culture period (up to 40 DIV). Myelinating cultures were fed
three times weekly. All culture media was supplemented with
0.5 µg ml−1 gentamycin.
Glia cells or myelinating cultures were plated onto
Proliferate® constructs as described above or onto poly-L-lysine
(PLL, Sigma-Aldrich) coated 13 mm glass coverslips (VWR) in
24-well plates. 20 ml PLL solution (13.3 μg ml−1 in dH2O) was
used per 96 coverslips. 500 μl culture media was added to wells
containing suspended construct inserts prior to cell seeding,
and a 50–100 μl cell suspension was added and incubated for
1 h. Wells were then topped up with a further 500 µl media.
Cultures were fed by removing 500 µl media surrounding the
insert and replacing with 500 µl media directly onto the insert.
2.5. Implantation in vivo
Contusion procedures were carried out on adult male Sprague-
Dawley rats as previously described,19 with modifications to
Biomaterials Science Paper































































































impact force and injury level as follows. Animals were anaes-
thetised with isoflurane and a laminectomy was performed to
expose the spinal cord at the C6 level. A midline impact with a
force of 175 kdyn was administered using an Infinite Horizon
impactor (Precision Systems Instrumentation). The contusion
site was marked by a 10-0 Ethicon suture in the dura, the
wound was closed and animals recovered in heated cabinets.
Implantation of Proliferate® constructs was performed 3
weeks after contusion, allowing sufficient time for cavity for-
mation. The injury site was re-opened and the contusion cavity
identified by the marking suture. An incision was made in the
dura at this site, revealing the fluid-filled cavity. Cavity fluid
was aspirated with care using a blunted 23 G needle. The
tubular construct containing parallel-aligned channels was cut
to the size of the injury cavity and implanted in alignment
with the cord. The material is compliant (sponge like) in con-
sistency and so could be eased through this slit-like opening,
displacing the edges of the dorsal columns to fill the cavity.
Once this is done, the spared tissue of the dorsal columns
spring back over the top of the biomaterial so that there is
minimal scarring or contact of the biomaterial with the dura.
Adherence problems and the potential to disrupt the integrity
of the tissue containing the injury site and implants were
therefore minimal due to the injury model and implant
approach adopted. The dura was closed again over the injury,
with a marking suture placed at the implantation site. In all
procedures, animals received pre- and post-operative analge-
sics (buprenorphine, 0.05 mg kg−1 and carprofen, 5 mg kg−−1,
s.c.). Saline (3–5 ml) and enrofloxacin (5 mg kg−1) were given s.
c. for 3 and 7 days respectively following surgery. If motor
impairment was detected following recovery, animals were
excluded from the study. Animal numbers and experimental
design is summarised in Fig. 1. Twenty-eight animals were
contused, of which 6 were excluded due to motor impairment
or inadequate recovery. No significant difference was observed
in animal weights at contusion and implantation procedures
(Fig. 4C and D), or in actual force and displacement achieved
(Fig. 4E–H). Subsequently, 7 animals received P–C implants, of
which 1 was excluded, and 9 received P–IK implants, of which
2 were excluded. Injury histology was assessed at short term (7
weeks) and long-term (6 months) time points.
2.6. Scanning electron microscopy [SEM]
Proliferate® constructs were mounted onto specimen stubs
(Agar Scientific) using conductive carbon tape and silver paint
was applied to construct edges. Stubs were coated with
10–20 nm gold palladium using a Quorum Q150 T high
vacuum coater. To visualise cell monolayers grown on the con-
struct, samples were prepared prior to coating using the fol-
lowing protocol. Cultures were fixed for 1 h at RT using 1.5%
glutaraldehyde in 0.1 M sodium cacodylate buffer. Samples
were then washed in 0.1 M sodium cacodylate buffer, before
being incubated in 1% osmium tetroxide in sodium cacodylate
buffer for 1 h. Samples were rinsed once more in buffer before
washing 3 × 10 min in dH2O, and incubating in 0.5% uranyl
acetate in dH2O for 1 h, protected from light. Samples were
then progressively dehydrated in the following ethanol concen-
trations: 30% (10 min), 50% (10 min), 70% (10 min), 90%
(10 min), absolute (4 × 5 min) and dried absolute (4 × 5 min).
The dried absolute ethanol solution contained a 3A molecular
sieve (Sigma-Aldrich) to remove moisture. A final drying step
was then carried out in hexamethyldisilazane (HDMS) before
mounting onto specimen stubs and coating as described.
Samples were visualised on a JEOL6400 scanning electron
microscope running at 10 kV, and images were captured using
the Olympus Scandium Software.
2.7. Western blot
Cells were lysed using CellLytic M containing protease inhibitor
cocktail (Sigma-Aldrich), and protein concentrations were deter-
mined using a BCA protein assay (ThermoFisher) according to
manufacturer’s instructions. Samples were run on tris-acetate gels
and transferred using the iBlot™ gel transfer device (Invitrogen).
Membranes were blocked in 5% milk in 0.2% Triton X-100 in TBS
(TBS-T) for 1 h before being incubated with anti-GFAP (1 : 100 000,
DAKO) for 2 h, and with anti-nestin (1 : 1000, Merck Millipore)
overnight at 4 °C. Blots were washed in TBS-T and incubated 1 h
Fig. 1 In vivo experimental design and injury parameters. [A] Summary
of experimental timeline. [B] Summary of total animals implanted. Body
weights were similarly distributed with no significant difference across
experimental groups [one-way ANOVA] both for animals perfused after 7
weeks [C] and 6 months [D]. Injury force [E, F] and displacement [G, H]
were similarly distributed across experimental groups [one-way ANOVA]
for animals implanted for both 7 weeks [E, G] and 6 months [F, H]. Error
bars = mean ± SEM.
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with secondary antibody (ECL rabbit IgG, ECL mouse IgG, GE
Healthcare). The protein loading control used was GAPDH
(1 : 1000, Abcam). Band intensities were quantified using Image-J
and normalised to GAPDH.
2.8. Immunocytochemistry
Cultures were fixed in 4% paraformaldehyde (PFA, in PBS at
PH 7.4) and permeabilised with 0.1% Triton X-100. Primary
antibodies (GFAP anti-rabbit 1 : 1000, DAKO; nestin anti-
mouse IgG1 1 : 500, SMI-31 anti-mouse IgG1 1 : 1000, both
Merck Millipore; β-III-tubulin anti-rabbit 1 : 1000, Abcam; PLP
1 : 00, hybridoma), were diluted in blocking buffer (0.2%
gelatin (Sigma-Aldrich) in PBS) and incubated for 1 h at RT.
Samples were washed three times in PBS before incubation
with fluorescent-conjugated secondary antibodies (AlexaFluor
1 : 1000, ThermoFisher) for 45 min at RT. Coverslips were
washed and mounted in an aqueous mounting medium
(25 mg ml−1, 4-diazabicyclo[2.2.2]octane (DABCO), Sigma-
Aldrich) containing Hoechst 33342 nuclear dye (NucBlue™,
ThermoFisher). Specimens were imaged using an Olympus
BX51 fluorescent microscope.
2.9. Histology
Animals were deeply anaesthetised with intraperitoneal
sodium pentobarbital (200 mg ml−1 Euthatal, Vericore) and
transcardially perfused with mammalian Ringer solution con-
taining 0.1% lidocaine. Animals were subsequently perfused
with 4% PFA in 0.1 M PBS (1 L PFA per animal). Spinal cord
segments containing the implant were dissected, leaving
approximately 10 mm tissue on either side of the injury site,
and submerged in cryoprotective post-fixation solution (30%
sucrose in 4% PFA) overnight. Tissue blocks were then sub-
merged in 30% sucrose in PBS for 24 h, or until the tissue was
observed to sink. Dura were removed, and cords were cut to
6–9 mm blocks containing the injury site, as determined by
injury extent. Blocks were notched dorso-ventrally before being
frozen in OCT. Sixty µm sections were cut sagittally using a
cryotome at −20 °C and incubated free-floating in 0.3 M PBS.
Sections were incubated in 50% ethanol for 30 min, washed
3× in PBS for 10 min, and incubated in primary antibodies (GFAP
1 : 1000, ThermoFisher; nestin anti-mouse IgG1 1 : 500, Merck
Millipore; Laminin anti-rabbit 1 : 500, Sigma-Aldrich; ED-1 anti-
mouse IgG1 1 : 500, BioRad; Neurofilament 200 anti-mouse IgG1
1 : 1000, Sigma-Aldrich) for 72 h at 4 °C. Sections were washed a
further 3 × 10 min in PBS before incubation with secondary anti-
bodies (AlexaFluor 1 : 1000, ThermoFisher) for 3 h at 4 °C, pro-
tected from light. Sections were then washed 3 × 10 min in PBS,
mounted on glass slides in aqueous mounting. Sealed slides were
stored at −20 °C, protected from light.
All sections were first examined using a Zeiss Axioplan epi-
fluorescence microscope to identify sections with the largest
cavity size, and to inspect immunolabeling. Representative sec-
tions selected were considered the most medial injury sec-
tions. Selected illustrative sections were scanned with a Zeiss
LSM 710 confocal system using X20 and X63 objective lenses.
Laser excitation wavelengths used for scanning were 405, 488,
561 and 633 nm. Tissue sections were scanned as tiled compo-
sites of multiple fields at low (×20) and high (×63) magnifi-
cation. Sections were scanned throughout the stained tissue to
accumulate a series of optical sections at 2–5 μm z separation.
Stacked images were projected into 2D maximum intensity
projections using Zeiss Zen software (Zeiss, Germany).
2.10. Quantification of cavity extent
Sagittal sections from each injury block were viewed under an
epifluorescence microscope and rostral and caudal limits of
the injury identified by the construct-tissue border signified by
construct autofluorescence, or in control sections from cavity
rims. Sections containing the most extensive sites (at least 3
per block) were selected for confocal imaging and the maximal
injury length and height were measured using ZEN lite 2010
software (Zeiss). Injury site width was quantified by counting
the number of sections containing the injury and multiplying
by section thickness (60 µm).
2.11. Statistical analysis
All statistical analysis was carried out using GraphPad Prism
software. A one-way ANOVA, with Dunnett’s or Tukey’s post hoc
tests where appropriate, was used for null hypothesis statistical
testing, where a p < 0.05 was considered statistically signifi-
cant. For in vitro analysis, N indicates biological replicates
incorporating a minimum of 3 technical replicates. For in vivo
analysis, N indicates separate animals.
3. Results
3.1. Proliferate® macro- and micro-structure
Mechanical and surface properties of Proliferate® in carboxyl-
functional form (P–C, highly cross-linked) are shown in Fig. 2.
For the present investigations, Proliferate® was synthesised in
for culture in two ways: (i) suspended in 24-well cell culture
inserts for 3D culture (Fig. 2A and C) and (ii) in tubular form
containing parallel-aligned cell guidance channels (Fig. 2B
and D). Microscopically, Proliferate® presents a heterogenic
beaded 3D topography. This heterogeneity creates natural
surface peaks and troughs to give rise to a heterogeneously
porous topography (Fig. 2E–G), tuneable by the degree of
cross-linking. Tensile testing revealed Proliferate®’s Young’s
modulus as 0.0128 kPa (Fig. 2H).
3.2. Astrocytes alter morphology and reactivity status on
Proliferate® in vitro
Astrocytic interactions with Proliferate® were investigated by
culturing neurosphere-derived primary neonatal rat astrocytes
on suspended Proliferate® cell culture inserts. These types of
astrocytes were used as they are a feature of the myelinating
cultures used to study CNS cell differentiation (section 3.3).
Cells were cultured on Proliferate® in carboxyl-functional (P–
C, high cross-linkage), amine-functional (P–N, low cross-
linkage) and IKVAV-coated (P–IK) forms. Astrocytes adopted a
more fibrous, branched morphology on all forms of
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Proliferate® compared to those grown on PLL-coated cover-
slips as visualised both by GFAP and nestin labelling (Fig. 3A)
and scanning electron microscopy (SEM, Fig. 3B). To investi-
gate astrocyte reactivity on Proliferate®, GFAP and nestin
expression in these cultures were quantified by western blot as
markers of astrocyte reactivity. GFAP upregulation is a well-
established marker for reactivity in vitro and in vivo, but not a
definitive one due to high expression in quiescence and
heterogeneous expression across CNS tissue and in culture.38
Nestin was therefore used as a supplementary reactivity
marker, as GFAP-nestin co-expression is an indicator of astro-
cyte reactivity in vivo39 and is characteristic of these cultures
in vitro.40 No significant difference was observed in GFAP
expression between astrocyte cultures on Proliferate® and con-
trols, however nestin was significantly lower on P–C and P–N
than on PLL-glass (Fig. 3C). Nestin expression also appeared
reduced on P–IK, although this difference was not significant.
3.3. Neuron survival and neurite extension and myelination
on Proliferate® in vitro
To investigate the potential of Proliferate® for guiding axonal
growth in the spinal cord, embryonic spinal cord suspensions
were cultured on astrocyte monolayers (myelinating cultures,
MCs) to examine the ability for cells to develop neurites and
for myelination. Neurites were present at both 33 DIV (Fig. 4A)
and 40 DIV (Fig. 4B). Myelination, as indicated by proteolipid
protein (PLP, green) immunolabelling, was delayed on con-
structs compared with PLL-glass. Myelination, as seen by the
formation of sheaths, is ordinarily observed on MCs at 28
DIV,37 however this is not clearly observed until 33 DIV on P–
IK, and 40 DIV on P–C and P–N (Fig. 4A and B), showing that
constructs can support myelination but that this is delayed
compared with cultures on PLL-glass. Axonal density appears
lower on constructs compared with PLL-glass, though this may
be due to axonal dispersal through the greater surface area in
Proliferate® constructs.
3.4. Proliferate® prevents long-term cavity expansion in vivo
Proliferate® was implanted into adult rat contusion spinal
cord injuries in vivo. As no difference was observed in vitro in
cell viability, growth and myelination between P–C and P–N,
only P–C was implanted as the non-coated construct control,
alongside the IKVAV-coated P–IK. GFAP labelling revealed a
distinct astrocytic border surrounding injury cavities and con-
Fig. 2 Proliferate® is a porous, structurally versatile and biocompatible polymer. Proliferate® was suspended in 24-well plate inserts for in vitro cell
culture [A, C, arrow indicates direction of cell seeding] and fabricated in tubular form with parallel-running channels for in vivo implantation [B, D].
SEM images show the porous heterogeneity of Proliferate® microstructure [E, scale bar = 100 μm], its characteristic 3D beaded topography in high
power [F, scale bar = 5 μm], and parallel-channels incorporated within Proliferate® in tubular form [G, scale bar = 100 μm]. [H] Mean mechanical
properties of Proliferate® as obtained by tensile testing [N = 6]. Data is shown for carboxyl-functional Proliferate® [P–C] only.
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struct implants in both implanted and non-implanted injuries
(Fig. 5) persistent at both 7 weeks (A–C) and 6 months post-
implantation (D–F). At both time points, however, the GFAP
cavity-tissue border in non-implanted injuries appears starker
than that of implanted injuries, with some astrocytes appear-
ing to enter scaffolds at the construct-tissue border in
implanted cavities (highlighted in Fig. 5A–Fii), suggesting that
construct-tissue borders are more permissive to astrocyte
growth and migration than cavity-tissue borders. GFAP deli-
neation coupled with non-specific staining of Proliferate® by
anti-nestin antibody reveals the full extent of cavities and
implants (Fig. 5B, C, E and F). Quantification of cavity extent
(Fig. 6) reveals no difference in cavity length 7 weeks post-
implantation (Fig. 6C) compared with non-implanted control
cavities, however significantly lower rostral-caudal cavity extre-
mities (cavity length) in P–C and P–IK are observed in
implanted injuries than in non-implanted injuries 6 months
post-implantation (p < 0.05. Fig. 6F). No significant difference
is observed in lateral cavity extremities (cavity width) between
implanted and non-implanted sections at either time point.
The longitudinal measurement is more significant in this
context as there is evidence that contusion cavities continue to
Fig. 3 Astrocytes adopt fibrous morphology and reduce nestin expression on Proliferate® compared with PLL-glass. [A] Neurosphere-derived
astrocytes cultured in serum-containing media on P–C, P–N and P–IK compared with PLL-glass, labelled with anti-GFAP [green] and anti-nestin
[red]. Astrocytes adopt a fibrous, branched morphology on all forms of the construct compared with flat, expansive morphologies on PLL-glass.
Astrocytes extend processes both over the construct surface [pink arrows] and across pores [A, blue arrows]. Construct surfaces are visualised by
non-specific anti-nestin labelling. Scale bar = 50 μm. [B] SEM images of neurosphere-derived astrocytes on P–C, P–N and P–IK compared with PLL-
glass, at 2000× magnification, illustrating cell-construct interactions. Construct appears mostly pink in colour, and cells blue/green. Some beaded
polymer construct segments also appear blue/green but are morphologically distinct from cells. Note that not all the construct surface is covered
by the pink area, some of the beads are the same colour as the cells. Astrocytes on PLL-glass extend processes from elevated nuclei [B, white
arrow], with undifferentiated neurospheres [B, blue arrow] also sporadically visible. On P–C, P–N and P–IK, astrocyte cell bodies are anchored to the
construct surface with fibres outstretched multi-directionally [B, yellow arrows]. Scale bar = 10 μm. [C] GFAP and nestin expression on P–C, P–N and
P–IK compared with PLL-glass after 7 DIV in serum-containing culture. Nestin expression is reduced on P–C and P–N compared with PLL-glass,
paralleled by non-significant trends towards nestin reduction on P–IK, and GFAP reduction on all construct substrates compared with PLL-glass.
Data from protein samples extracted from confluent astrocytes at 7 DIV [one-way ANOVA with Dunnett’s post-hoc test, P < 0.05. Error bars: mean ±
SEM. N = 4].
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expand in this plane for up to 6 months after injury whereas
changes in width are minimal (J. S. Riddell & M. Hadian,
unpublished observations). It is notable that channel integrity
does not appear to be maintained in implants, with only few
open channels visible on histological examination (highlighted
by dashed lines).
3.5. Proliferate® induces extensive vascularisation and
cellular influx in vivo
Laminin labelling revealed extensive vascularisation through-
out construct implants both 7 weeks and 6 months post-
implantation (Fig. 7, ESI Fig. 2†). Clear laminin vessels are
present throughout P–C and P–IK implanted constructs, abun-
dantly surrounded by nuclei (Fig. 7). Notably, vascularisation
and cellular influx occurred throughout constructs both in gui-
dance channels and in construct-dense regions. Non-specific
construct labelling by Hoechst 33342 nuclear stain is observed,
however nuclei are identifiable by morphology (ESI Fig. 3†).
3.6. Microglial response to Proliferate® in vivo
To assess the immunological response to construct implants,
microglia and macrophages in injury cavities and construct
implants were visualised by anti-ED-1 labelling (green, Fig. 8).
Although microglia were present in constructs both centrally
and at the construct-tissue border, they accounted for only a
small population of Hoechst 33342 stained nuclei within and
surrounding constructs at both 7 weeks and 6 months post-
implantation (Fig. 8A and B). No clear difference was observed
in microglial response between 7 weeks and 6-month time
points (see ESI Fig. 2†). In non-implanted injuries, a distinct
tissue-cavity border was observed through which microglia and
other cells did not cross due to lack of matrix infilling acting
as a cell support (Fig. 8C). No clear difference was visible in
microglial levels surrounding non-implanted injury cavities
and construct-implanted injuries.
3.7. Neurite growth into Proliferate®-implanted lesions
Axonal outgrowth from perilesional zones into construct
implants remains limited at both short- and long-term time
points, as visualised by neurofilament labelling (Fig. 9). No
clear difference was observed in axonal growth into constructs
between 7 weeks and 6-month time points. Inside constructs,
axons remain sparse at both time points, and are limited to
segments of undisrupted guidance channels (Fig. 9A). At the
construct tissue border, however, axons appear to grow out
from perilesional zones into Proliferate® implants with regu-
larity in segments with intact guidance channels providing
spaces for entry (Fig. 9B). Non-implanted injuries maintain a
binary axonal border between tissue and injury cavity, with no
axonal outgrowth observed (Fig. 8C).
4. Discussion
Previously, we demonstrated in vitro the potential of aligned
micropatterned ε-polycaprolactone (PCL) as an biomaterial for
SCI,41,42 however due to concerns pertaining to the stiffness
disparity between these PCL scaffolds and the spinal cord, our
findings had limited potential for in vivo application. We
found the stiff PCL was hard to position into a lesion and did
not appear to integrate well (unpublished observations).
Therefore, pεK based Proliferate® scaffolds were selected as an
alternative implantable scaffold with material properties more
closely comparable to spinal cord tissue. With no precondi-
tioning, the Young’s modulus of the adult rat spinal cord has
Fig. 4 Neuronal survival and myelination on Proliferate®. Myelinating cultures labelled with anti-SMI31, anti-PLP and Hoechst 33342, at [A] 33 DIV
and [B] 40 DIV on P–C, P–N and P–IK compared with PLL-glass. Myelination is delayed on 3D Proliferate® substrates compared with glass. Scale
bar = 20 μm.
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Fig. 5 Anti-GFAP and anti-nestin labelling delineates construct-tissue border and indicates cavity extent. [A] Anti-GFAP [green] labelling reveals dis-
tinct construct-tissue astrocytic borders of injury cavities at both 7 weeks [A–C] and 6 months [D–F] post-implantation. GFAP + cells are sparsely
seen entering the constructs at both time points [as highlighted in A–F ii]. Non-specific nestin labelling [red] allows construct visualization. Some
non-specific weakly fluorescent anti-GFAP construct staining is also observed [notable in F]. Parallel channels fabricated in constructs are largely
absent, with channels only sparsely visible [highlighted by dashed lines, notable in F]. Scale bars [i] 500 μm, [ii] 125 μm. Tile-scan confocal images,
20× magnification, 2–5 μm z-separation.
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been estimated at 0.15–0.74 kPa.43 Proliferate® in carboxyl-
functional form has a Young’s modulus of 0.0128 kPa, com-
parable closely to these recent findings. We therefore con-
cluded that Proliferate® is mechanically compatible with the
rat spinal cord and proceeded to test for corresponding CNS
biocompatibility using various neural cell cultures.
Astrocytes play a large role in the glial scar following SCI,
and are highly responsive to biomaterial topographies.41,44 On
the three different Proliferate® substrates tested, astrocytes
adopted a stellate, ramified morphology distinct from the flat,
expansive polygonal morphology observed on flat PLL-glass
coverslips. This morphology is typical of astrocytes in vivo,45
therefore suggests that Proliferate® surface topography is com-
parable to the 3D tissue milieu in which these cells inherently
reside. The heterogeneously beaded surface topography of
Proliferate® is more reminiscent of 3D spinal cord tissue than
flat glass coverslips typically used for cell culture. Consistent
with our findings, astrocytes adopt ramified morphologies on
a range of other 3D biomaterials, including alginate, collagen
type 1, collagen-hyaluronic acid (HA) and collagen-HA-matrigel
hydrogels,46–48 polyurethane nanofibers49 and hydrophobic tri-
palmitin.50 It has been shown that when astrocytes are cul-
tured in 3D hyrogel their morphology resembles perivascular
astrocytes, but they also from round, stellate or bipolar shapes
within a few days. The latter is induced by aligned
microcolumns,47,51–53 however the branched morphology is
considered most representative of in vivo phenotypes.45
Moreover, it has been shown that astrocytes form a reparative
phenotype as assessed by reduced GFAP expression and fewer
F-/G-actin stress fibres when plated on 3D electrospun bios-
caffolds relative to 2D astrocytes.54 The broad consensus in the
field is that for better understanding of astrocytic behaviour,
particularly with respect to the characterisation of the spec-
trum of astrocyte reactivity states, astrocyte culture systems
must be optimised to promote representative in vivo astrocytic
states.40,55 To this aim, other modifications of the culture
Fig. 6 Proliferate® prevents chronic cavity expansion. The percentage of the total cord width occupied by the injury cavity [A, D] and the maximum
cavity width in each injury [B, E] do not differ significantly across experimental groups 7 weeks or 6 months post-implantation [one-way ANOVA].
Maximum cavity length does not differ significantly across experimental groups at 7 weeks post-implantation [C], but is lower in P–C and P–IK-
implanted injuries at 6 months post-implantation compared to non-implanted controls [F, one-way ANOVA].
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environment, separate from substrate characteristics, have also
been used to promote a ramified morphology. Media modifi-
cations, including the removal of serum from culture media,
and immunopanning are one example of this, being reported
to promote astrocyte phenotypes closer to those seen in vivo
both morphologically and, in protein and gene expression
profiles.56–58
No definitive protein markers of astrocyte reactivity have
thus far been identified, though increased GFAP expression
has long been the accepted hallmark.55,59 However, GFAP is
largely expressed by quiescent astrocytes and astrocytes
in vitro. Therefore, alongside quantification of GFAP in cul-
tures on Proliferate® and PLL-glass, we also quantified nestin
expression as an indicator of reactivity. Nestin is an intermedi-
Fig. 7 Extensive vascularisation is observed in construct-implanted injuries. Anti-laminin staining shows tubular blood vessels [highlighted by
arrows and insert] present extensively and uniformly throughout P–C [A, C] and P–IK [B, D]-implanted injuries both 7 weeks [A, B] and 6 months [C,
D] post-implantation. In highlighted regions (inset), construct is shown in grey. Scale bar = 50 μm. Confocal images, 63× magnification, 2–5 μm
z-separation.
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ate filament protein predominantly expressed in neural
development,60,61 and re-expressed by reactive astrocytes.62,63
Astrocytic nestin expression is common in traditional cell
culture conditions, however is absent in non-reactive spinal
cord in vivo.39 In traditional astrocyte culture, nestin
expression is lower on non-coated Proliferate® (P–C, P–N) than
on 2D PLL-glass, indicating an altered astrocyte reactivity state
on the construct reminiscent of in vivo quiescence. As the
astrocyte-mediated glial scar remains one of the greatest bar-
riers to CNS repair, the potential induction of a quiescent-like
phenotype by Proliferate® could be viewed positively, however
it is important to note that astrocyte reactivity and the glial
scar are also implicated in several beneficial functions along-
side detrimental ones.38
Fig. 8 Microglial response to Proliferate®. Anti-ED1 antibody labelling [green] shows microglia present [A] in the center and [B] at the edges of P–C
and P–IK implanted injuries both 7 weeks and 6 months post-implantation. Microglia did not migrate into non-implanted cavities due to a lack of
matrix infilling to act as a growth or migration substrate, resulting a clear tissue-cavity border at the lesion edge [C]. Scale bar = 50 μm. Confocal
images, 63× magnification, 2–5 μm z-separation.
Paper Biomaterials Science































































































Neuronal morphological differences are also seen between
PLL-glass and Proliferate® substrates. On flat glass surfaces,
axons appear to grow largely in parallel outwards from cell
body bundles dispersed throughout coverslips.37 Conversely,
on Proliferate® substrates cell bodies appear more evenly dis-
persed throughout the culture without bundling, and axonal
orientation is no longer organised in parallel fashion. Axonal
alignment in the spinal cord is important for physiological
function, therefore for Proliferate® to be viable as an implanta-
ble material, the incorporation of guidance cues into the
material may be crucial. Myelination was delayed in these cul-
tures on Proliferate®, continuous with our previous findings
Fig. 9 Neurite outgrowth can be seen within Proliferate®. Anti-neurofilament [red] staining demonstrates axonal outgrowth from perilesional
zones into construct implants although limited at both short- and long-term time points. [A] Axons can be detected inside constructs [highlighted
by arrows], although remain sparse and are limited to segments of undisrupted guidance channels. [B] At the construct tissue border, axons can be
seen to extend from perilesional tissue into Proliferate® implants [tissue-construct border highlighted by dashed lines]. [C] Non-implanted injuries
maintain a binary axonal border between tissue and injury cavity, with no axonal outgrowth observed [tissue-cavity border highlighted by lines].
Confocal images, 63× magnification, 2–5 μm z-separation.
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on PCL.41 This may due to a lack of neurite organisation or a
substrate-specific delay in oligodendrocyte maturation, as was
postulated in our PCL study. This also may be due to the differ-
ence in stiffness between glass and proliferate which can also
affect aspects of differentiation.64 Myelination was, however,
observed on P–IK earlier than on P–C and P–N in our study.
However the important observations is that all CNS glial cells
can interact, differentiate and form myelin sheaths on
Proliferate®.
For implantation in vivo, Proliferate® was fabricated in
tubular form containing parallel channels for more organised
guidance. However, upon histological examination 7 weeks/
6 months following implantation, channels did not remain
intact, with only remnants of the channel organisation visible
at both time points. We postulate that due to the soft nature of
Proliferate®, channel walls are prone to adhering and/or col-
lapsing upon compression induced by surgical procedures and
movement of the spinal column. We believe that by using
soluble fibres of larger diameter to fabricate channels,
channel integrity may be more consistently maintained. At
6 months following implantation, non-implanted injuries were
more extensive, as indicated by higher rostral-caudal cavity
lengths, than those implanted with Proliferate®. This indicates
stabilisation of the injury by adhesion of constructs to perile-
sional tissue, preventing excessive tissue dieback. As rostral-
caudal cavity lengths were not significantly different in
implanted than in non-implanted injuries at 7 weeks post-
implantation, it suggests that this dieback is a chronic injury
response. A distinct astrocytic border was observed surround-
ing constructs in both short and long-term implantations, as
is expected of typical non-implanted contusion injuries,
however the reactivity status of these astrocytes is unclear. The
prevalence of quiescent-like astrocytic phenotypes on
Proliferate® substrates in vitro with low nestin expression
could be indicative of a similar phenotype in vivo, however due
to non-specific construct labelling by the nestin antibody, co-
expression of GFAP and nestin could not be accurately quanti-
fied by immunohistochemistry. We did note, however, spora-
dic evidence of visible astrocytic movement from the perile-
sional zones into constructs in areas of channel integrity at the
border with existing gaps for inward cellular movement.
Similar astrocytic bordering has been observed surrounding
collagen nanofiber implants in C3 rat hemisection injury65
and T10 rat contusion injuries implanted with poly(lactic-co-
glycolic acid) (PLGA) and PCL.66 Astrocytic ingrowth was,
however, observed in collagen scaffold implanted
T8–10 hemisection67 and transection68 injuries, and in poly
(N-[2-hydroxypropyl]methacrylamide) hydrogel (NeuroGel™)
implanted into T6–7 complete cat transections, where glial
scar formation was attenuated.69
Evidently, several non-astrocytic cells do move into
Proliferate® implants, as nuclei that are not associated with
either GFAP or nestin are visible extensively throughout con-
structs at both 7 weeks and 6 months post-implantation, as is
extensive vascularisation. The presence of vascular structures
across constructs lays the foundations for cell ingrowth. The
identity of these cells, however, remains elusive. Microglia are
one cell type ordinarily prevalent in SCI, however we found
that microglia represent only a minority of cells in construct
implants at both time points investigated, appearing in similar
quantities both in the centre of constructs and at astrocyte-
rich construct borders.
The ultimate goal of construct implantation is to promote
neuronal regeneration across the injury site. However, as pre-
viously discussed, guidance cues are paramount to organised
axonal growth and alignment. Cell guidance channels are one
example of such cues,11 however as previously mentioned, gui-
dance channels incorporated into P–C and P–IK implants did
not retain integrity once implanted. Organised axonal exten-
sion across injuries were therefore not possible. Congruently,
axonal growth into construct implants was observed only in
areas where intact channels existed. It was promising,
however, that in such regions axons were able, though in small
number, to grow into constructs. In these areas, some axons
were observed in construct centres as well as edges, particu-
larly in implants maintained to 6 months.
5. Conclusion
The therapeutic value of biomaterial implantation in SCI is
multi-faceted. Our findings have shown a novel material,
Proliferate®, to possess the necessary material properties for
this purpose. We have demonstrated the compatibility of CNS
cells with Proliferate® in vitro and in vivo, showing
Proliferate®’s potential both as a solo implant, and as a base
upon which other therapeutic compounds can be immobilised
for delivery of other bioactive molecules to the injury site, for
example molecules affecting the glial scar or facilitation of
axonal regeneration. It will then be appropriate to investigate
whether these mechanistic actions translate into tangible
improvements in functional outcome by carrying out behav-
ioural or electrophysiological assessments.
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